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ABSTRACT
Background: Eosinophil and lymphocyte counts are
commonly performed in clinical practice. Previous
studies provide conflicting evidence of association with
cardiovascular diseases.
Methods: We used linked primary care,
hospitalisation, disease registry and mortality data in
England (the CALIBER (CArdiovascular disease
research using LInked Bespoke studies and Electronic
health Records) programme). We included people aged
30 or older without cardiovascular disease at baseline,
and used Cox models to estimate cause-specific HRs
for the association of eosinophil or lymphocyte counts
with the first occurrence of cardiovascular disease.
Results: The cohort comprised 775 231 individuals,
of whom 55 004 presented with cardiovascular disease
over median follow-up 3.8 years. Over the first
6 months, there was a strong association of low
eosinophil counts (<0.05 compared with 0.15–
0.25×109/L) with heart failure (adjusted HR 2.05; 95%
CI 1.72 to 2.43), unheralded coronary death (HR 1.94,
95% CI 1.40 to 2.69), ventricular arrhythmia/sudden
cardiac death and subarachnoid haemorrhage, but not
angina, non-fatal myocardial infarction, transient
ischaemic attack, ischaemic stroke, haemorrhagic
stroke, subarachnoid haemorrhage or abdominal aortic
aneurysm. Low eosinophil count was inversely
associated with peripheral arterial disease (HR 0.63,
95% CI 0.44 to 0.89). There were similar
associations with low lymphocyte counts (<1.45 vs
1.85–2.15×109/L); adjusted HR over the first 6 months
for heart failure was 2.25 (95% CI 1.90 to 2.67).
Associations beyond the first 6 months were weaker.
Conclusions: Low eosinophil counts and low
lymphocyte counts in the general population are
associated with increased short-term incidence of heart
failure and coronary death.
Trial registration number: NCT02014610; results.
INTRODUCTION
Eosinophils and lymphocytes are two types of
white blood cell (leucocyte). While other
types of white blood cells such as neutrophils
and monocytes are known to be involved in
inﬂammatory processes that contribute to
atherosclerosis,1 the role of eosinophils and
lymphocytes in cardiovascular diseases is less
well deﬁned. Observational studies show
KEY QUESTIONS
What is already known about this subject?
▸ Inflammation is a key pathological process
underlying atherosclerosis and cardiovascular
diseases, and different types of white blood
cells (including eosinophils and lymphocytes)
have specific roles in inflammation.
▸ It is not known how strongly eosinophil and
lymphocyte counts in healthy populations are
associated with the incidence of a wide range of
pathologically diverse cardiovascular diseases.
The few existing studies had a small number of
participants or studied a limited range of cardio-
vascular diseases.
What does this study add?
▸ In a healthy population without pre-existing car-
diovascular disease, low eosinophil and lympho-
cyte counts were associated with increased
short-term incidence of heart failure, unheralded
coronary death, ventricular arrhythmia/sudden
cardiac death and non-cardiovascular death.
▸ These associations were specific; eosinophil and
lymphocyte counts were not associated with
incidence of angina, non-fatal myocardial infarc-
tion or stroke among people without pre-existing
cardiovascular disease.
How might this impact on clinical practice?
▸ Clinicians should be aware that low eosinophil
counts (in the range which is currently reported
as ‘normal’) may be associated with increased
short term risk of heart failure and death.
▸ Therapies which result in lower eosinophil
counts, such as anti-interleukin-5 therapies for
asthma, should be monitored for any increased
risk of cardiovascular events in clinical trials and
postmarketing surveillance.
Shah AD, Denaxas S, Nicholas O, et al. Open Heart 2016;3:e000477. doi:10.1136/openhrt-2016-000477 1
Cardiac risk factors and prevention
worse prognosis among patients with heart failure with
low eosinophil counts2 or low lymphocyte counts,3–5
prompting the question as to whether counts of these
types of cell are also associated with onset of cardiovas-
cular diseases in previously healthy people.
The main physiological role of eosinophils is thought to
be in restoring tissue homoeostasis after inﬂammation.6
High eosinophil counts may be due to conditions such as
asthma,7 but clinicians tend not to attribute particular sig-
niﬁcance to low or moderate eosinophil counts. Eosinophil
counts increase acutely after myocardial infarction (MI)8
and large numbers are found in coronary thrombi.9 Two
small cohort studies (Hiroshima and Nagasaki study10 and
Caerphilly study11) found that higher eosinophil count was
associated with greater incidence of coronary heart disease
among healthy people (see online supplementary table
S1). However, in patients undergoing percutaneous coron-
ary intervention12 or those in critical care,13 lower eosino-
phil counts were associated with worse prognosis. The
previous evidence relating eosinophil counts to cardiovas-
cular diseases is thus scarce and contradictory.
Lymphocytes comprise a range of different cell types
with different roles in the immune system.14 Low total
lymphocyte count is associated with malnutrition and
immune suppression,15 and observational studies have
shown that it is associated with poor prognosis in patients
with ST elevation MI.16 However, studies investigating
total lymphocyte counts and cardiovascular diseases in
the general population did not ﬁnd signiﬁcant associa-
tions10 11 17–26 (see online supplementary table S2).
Previous studies investigating associations of eosinophil
and lymphocyte counts with future risk of cardiovascular
disease were limited by small size (no more than 2000
events), and they investigated only a narrow range of car-
diovascular end points. It is not known how eosinophil
and lymphocyte counts are associated with stroke, heart
failure and peripheral arterial disease (PAD), or
whether short-term and long-term associations differ.
These cell counts are included in the complete blood
count (full blood count), one of the most commonly
performed blood tests in medical practice. Thus, large
databases of routinely collected laboratory results and
clinical information can provide a way of investigating
the epidemiology of eosinophil and lymphocyte counts,
and their association with cardiovascular diseases, at
scale. Our new study harnessed the large CALIBER
(CArdiovascular disease research using LInked Bespoke
studies and Electronic health Records) linked electronic
health record database27 (over 700 000 individuals and
50 000 cardiovascular events) to examine associations of
eosinophil and lymphocyte counts with a diverse range
of initial presentations of cardiovascular disease.
METHODS
Study population
The study population was drawn from the CALIBER pro-
gramme,27 which has been used for a series of studies
investigating risk factors and the onset of cardiovascular
diseases.28–32 CALIBER links four sources of electronic
health data in England: primary care health records
(coded diagnoses, clinical measurements and prescrip-
tions) from general practices contributing to the
Clinical Practice Research Datalink33 (CPRD), coded
hospital discharges (Hospital Episode Statistics, HES),
the Myocardial Ischaemia National Audit Project34
(MINAP) and death registrations (see online supple-
mentary methods for more details). The patients in
CALIBER are broadly representative of the English
population.27 The study period was January 1998 to
March 2010, and individuals were eligible for inclusion
when they were at least 30 years of age and had been
registered for at least 1 year in a practice which met
research data recording standards. The study start date
(index date) for each participant was the date of the
ﬁrst full blood count measurement recorded in CPRD
while the participant was eligible. Patients with a prior
history of cardiovascular disease and women with a preg-
nancy record within 6 months of the start of the study
were excluded. Pregnancy or any other event occurring
after study entry was not used as an exclusion criterion.
Approval was granted by the Independent Scientiﬁc
Advisory Committee of the Medicines and Healthcare
products Regulatory Agency (protocol 12_153) and the
MINAP Academic Group. This study is registered with
ClinicalTrials.gov, number NCT02014610.
Exposure
The main exposures were eosinophil and lymphocyte
counts as recorded in primary care. If a patient had
more than one measurement on a given day, the values
were aggregated by taking the mean. We analysed
eosinophil and lymphocyte counts as categorical vari-
ables in order to avoid presuming a particular shape for
the association with cardiovascular diseases. There were
no clinically obvious cutpoints or consistent deﬁnitions
of ‘normal’ lymphocyte or eosinophil counts in the lit-
erature. In the absence of a clear rationale for choosing
speciﬁc cutpoints, we chose to study quintiles; however,
the number of decimal places varied between laborator-
ies (units: cells×109/L) and the absolute values of
eosinophil counts were small relative to the precision of
recording (see online supplementary ﬁgure S1). In
order to avoid biasing the category allocation by preci-
sion, we manually adjusted the eosinophil category
boundaries, so that the second decimal place was 5, thus
ensuring that any values recorded to two decimal places
would end up in the same category if they were
recorded to only one decimal place. We derived quintile-
based categories for lymphocyte counts by a similar
method. All category intervals were closed at the lower
bound and open at the upper bound, that is, ‘0.05 to
0.15’ includes 0.05 but not 0.15.
Eosinophil and lymphocyte counts can be affected by
many factors such as infections, autoimmune diseases,
medication and haematological conditions. We sought to
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differentiate between a patient’s long-term ‘stable’ leuco-
cyte proﬁle and results obtained when the patient had an
‘acute’ condition which may alter leucocyte counts. We
used other information in the electronic health record to
assess whether the patient was clinically ‘acute’ or ‘stable’
at the time of the blood test, adapting a set of criteria
proposed by the eMERGE consortium35 (electronic
Medical Records and Genomics) for studying genetic
determinants of the stable leucocyte counts: in hospital
on the date of blood test, vaccination in the previous
7 days, anaemia diagnosis within the previous 30 days,
symptoms or diagnosis of infection within the previous
30 days, prior diagnosis of myelodysplastic syndrome,
prior diagnosis of haemoglobinopathy, cancer chemo-
therapy or granulocyte colony stimulating factor (G-CSF)
within 6 months before index date, or the use of drugs
affecting the immune system such as methotrexate or
steroids within the previous 3 months. Patients with HIV,
splenectomy or on dialysis were excluded from this study,
as their leucocyte counts may be difﬁcult to interpret.
In secondary analyses, we explored associations
between onset of cardiovascular diseases and the mean
of the ﬁrst two ‘stable’ measurements of eosinophil
count taken since the start of eligibility. We also carried
out a sensitivity analysis excluding patients with a history
of prior loop diuretic use, as they might have symptoms
of heart failure without a formal diagnosis.
Covariates
We extracted demographic variables, cardiovascular risk
factors, comorbidities, acute conditions and prescrip-
tions around the time of the blood test from CPRD. For
continuous covariates, we used the most recent value in
the year prior or up to 1 day after the full blood count
measurement. We also extracted the ﬁrst measurement
after this time window and the most recent measure-
ment before the time window, along with the timing of
these measurements relative to the index date, to use as
auxiliary variables for multiple imputation. We extracted
hospitalisation records and comorbidities additionally
from HES.
Follow-up and cardiovascular end points
Patients were followed up while registered at the practice
until the occurrence of an initial presentation of cardio-
vascular disease, death or transfer out of the practice.
The primary end point was the ﬁrst record of one of
the following cardiovascular presentations in any of the
data sources: coronary artery disease (categorised as
stable angina, unstable angina, non-fatal MI, unheralded
coronary death or unspeciﬁed), heart failure, transient
ischaemic attack, stroke (categorised as ischaemic, haem-
orrhagic or unspeciﬁed), subarachnoid haemorrhage,
PAD, abdominal aortic aneurysm and a composite of
ventricular arrhythmia, implantable cardioverter deﬁbril-
lator, cardiac arrest or sudden cardiac death. Any events
occurring after the ﬁrst cardiovascular presentation were
ignored. End point deﬁnitions are described in online
supplementary methods, and phenotyping algorithms
are available on the CALIBER portal (http://www.
caliberresearch.org/portal/).
Statistical analysis
We generated cumulative incidence curves by category
of eosinophil count under a competing risks framework.
We used the Cox proportional hazards model to gener-
ate cause-speciﬁc hazards for association of eosinophil
or lymphocyte count category with the different cardio-
vascular end points. We designated the middle category
as the reference because we did not predetermine the
direction or shape of association we were looking for.
HRs were adjusted for age (linear and quadratic), sex,
age/sex interaction, index of multiple deprivation, eth-
nicity, smoking status, diabetes, body mass index, systolic
blood pressure, estimated glomerular ﬁltration rate,
high-density lipoprotein cholesterol, total cholesterol,
atrial ﬁbrillation, inﬂammatory conditions (autoimmune
conditions, chronic obstructive pulmonary disease or
inﬂammatory bowel disease), cancer, statin use, blood
pressure medication and acute conditions at the time of
blood testing as listed previously. The baseline hazard
was stratiﬁed by practice and sex. We handled missing
baseline covariate data by multivariate imputation using
chained equations using Random Forest multiple imput-
ation models,36 as described more fully in the online
supplementary methods.
In supporting analyses, we examined linear associa-
tions with eosinophil count as a continuous variable,
which would have greater power to detect linear associa-
tions and would enable such associations to be commu-
nicated in a more concise way. We plotted Schoenfeld
residuals to assess the proportional hazards assumption,
and split the follow-up time if HRs changed over time.
We investigated interactions with age and sex, and
carried out a sensitivity analysis excluding patients with
probable symptomatic heart failure (as evidenced by
loop diuretic prescription in the absence of a formal
diagnosis of heart failure). We also investigated the vari-
ability of stable eosinophil and lymphocyte counts.
Statistical analyses were performed using R V.2.14.1 for
Linux.
RESULTS
We included 621 052 patients with differential leucocyte
counts while clinically ‘stable’ and 154 179 patients with
differential leucocyte counts performed during acute
illness or treatment (see online supplementary ﬁgure S2
and table S3). We observed 55 004 initial presentations
of cardiovascular disease over median 3.8 (IQR 1.7–6.0)
years follow-up; 9711 occurred within the ﬁrst 6 months.
Of the remaining patients, 32 591 died of non-
cardiovascular causes, 99 622 left the practice during the
study period and were censored, and 588 014 were still
registered with the practice at the end of the study
period.
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Baseline characteristics
Lower eosinophil and lymphocyte counts were not asso-
ciated with major cardiovascular risk factors. Low eosino-
phil count was associated with female gender, black
ethnicity and cancer, whereas higher eosinophil count
was associated with male sex, deprivation, South Asian
ethnicity, higher body mass index and atopy (table 1, see
online supplementary table S4). Low lymphocyte count
was associated with cancer, in common with eosinophil
counts, but the association with ethnicity was different:
people of black ethnicity tended to have higher lympho-
cyte counts (table 1, see online supplementary table S5).
Eosinophil and lymphocyte counts in the lowest categor-
ies were more likely to be taken under acute conditions
(see online supplementary tables S6 and S7).
Cumulative incidence of cardiovascular disease by
eosinophil and lymphocyte count
Crude cumulative incidence curves showed that indivi-
duals with low eosinophil or lymphocyte counts had a
greater incidence of heart failure as the initial presenta-
tion of cardiovascular disease, at least over the ﬁrst few
months (ﬁgure 1), but there was no apparent
association with non-cardiac presentations of cardiovas-
cular disease (ﬁgure 2).
HRs for association of eosinophil and lymphocyte counts
with initial presentation of cardiovascular disease
In multiply adjusted analyses, there were associations of
low eosinophil counts (<0.05 compared with the middle
category, 0.15–0.25×109/L) with incident heart failure
(adjusted HR 1.39; 95% CI 1.26 to 1.54), unheralded
coronary death (HR 1.29, 95% CI 1.12 to 1.50) and ven-
tricular arrhythmia or sudden cardiac death (HR 1.49,
95% CI 1.12 to 2.00). However, there were no such asso-
ciations with stable angina (HR 0.93, 95% CI 0.84 to
1.03), non-fatal MI (HR 1.00, 95% CI 0.89 to 1.12) or
ischaemic stroke (HR 1.02, 95% CI 0.88 to 1.19; see
online supplementary ﬁgure S3). Low lymphocyte
counts (<1.45 compared with 1.85–2.15×109/L) also
showed associations with heart failure (HR 1.61, 95% CI
1.48 to 1.74) and unheralded coronary death (HR 1.27,
95% CI 1.13 to 1.42; see online supplementary ﬁgure
S4). Low eosinophil counts (<0.05 compared with 0.15–
0.25×109/L) were associated with signiﬁcantly increased
risk of non-cardiovascular death (HR 1.79, 95% CI 1.72
Table 1 Characteristics of patients with low eosinophil or low lymphocyte counts
Patient group All patients
Low eosinophils
(<0.05×109/L)
Low lymphocytes
(<1.45×109/L)
N patients 775 231 44 112 133 220
Women, n (%) 461 956 (59.6%) 29 990 (68.0%) 80 119 (60.1%)
Age, median (IQR) 52.4 (41.4–64.6) 52 (39.8–66.8) 55.8 (43.4–70.4)
Most deprived quintile, n (%) 132 971 (17.2%) 6931 (15.8%) 18 982 (14.3%)
Ethnicity, n (%)
White 445 034 (92.8%) 25 511 (91.7%) 80 558 (95.3%)
South Asian 13 450 (2.8%) 552 (2.0%) 1134 (1.3%)
Black 9974 (2.1%) 1051 (3.8%) 1214 (1.4%)
Other 11 320 (2.4%) 714 (2.6%) 1598 (1.9%)
Missing 295 453 (38.1%) 16 284 (36.9%) 48 716 (36.6%)
Smoking status, n (%)
Never 386 702 (52.6%) 25 034 (61.0%) 76 478 (61.6%)
Ex 177 199 (24.1%) 8840 (21.5%) 30 682 (24.7%)
Current 171 021 (23.3%) 7158 (17.4%) 16 925 (13.6%)
Missing 40 309 (5.2%) 3080 (7.0%) 9135 (6.9%)
Most recent value within 1 year prior to index date, median (IQR)
Systolic blood pressure 136 (121–150) 133 (120–148) 136 (120–150)
Body mass index 27.0 (23.8–31.1) 25.0 (22.0–28.5) 25.5 (22.5–29.0)
Total cholesterol 5.5 (4.8–6.2) 5.4 (4.6–6.1) 5.3 (4.6–6.1)
HDL cholesterol 1.4 (1.1–1.7) 1.5 (1.2–1.8) 1.5 (1.2–1.8)
eGFR 81.9 (68.8–95.1) 81.4 (67.6–95.4) 78.9 (65.1–92.1)
Diagnoses on or before index date, n (%)
Atrial fibrillation 7722 (1.0%) 555 (1.3%) 2358 (1.8%)
Cancer 47 521 (6.1%) 3895 (8.8%) 13 109 (9.8%)
Diabetes 37 127 (4.8%) 1502 (3.4%) 5807 (4.4%)
Asthma or atopy 212 900 (27.5%) 9783 (22.2%) 36 750 (27.6%)
COPD 15 021 (1.9%) 863 (2.0%) 3250 (2.4%)
Connective tissue disease 21 859 (2.8%) 1680 (3.8%) 5629 (4.2%)
Inflammatory bowel disease 8646 (1.1%) 704 (1.6%) 2337 (1.8%)
COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein.
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Figure 1 Cumulative incidence curves for different initial presentations of cardiac disease by category of eosinophil and
lymphocyte count. Shading denotes 95% CIs.
Figure 2 Cumulative incidence curves for non-cardiac initial presentations of cardiovascular disease by category of eosinophil
and lymphocyte count. Shading denotes 95% CIs.
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to 1.86), as were low lymphocyte counts (<1.45 com-
pared with 1.85–2.15×109/L; HR 1.65, 95% CI 1.59 to
1.71), with no clear preponderance for a particular
cause of death (see online supplementary tables S8 and
S9). Mutual adjustment of lymphocyte and eosinophil
counts made very little difference to the HRs (see
online supplementary ﬁgures S5 and S6).
In models adjusted only for age and sex, the lowest
eosinophil category (<0.05 compared with 0.15–
0.25×109/L) was associated with reduced hazard of
stable angina (HR 0.83, 95% CI 0.75 to 0.92) and PAD
(HR 0.81, 95% CI 0.70 to 0.92; see online supplemen-
tary ﬁgure S7); there was a similar trend of lower risk
with lower eosinophil count for non-fatal MI. These asso-
ciations were not present with multiple adjustment (see
online supplementary ﬁgure S3).
Supporting analyses
We found that associations with low eosinophil counts
were stronger in the ﬁrst 6 months and weak or null
thereafter (ﬁgure 3, see online supplementary ﬁgure
S8). In the ﬁrst 6 months, the HR associating low eosino-
phil counts (<0.05 compared with 0.15–0.25×109/L)
with incident heart failure was 2.05 (95% CI 1.72 to
2.43). The corresponding HR for unheralded coronary
death was 1.94 (95% CI 1.40 to 2.69), and for ventricular
arrhythmia or sudden cardiac death 3.05 (95% CI 1.48
to 6.28), as shown in ﬁgure 3. Similar associations were
shown for low lymphocyte counts (ﬁgure 3, see online
supplementary ﬁgure S9).
Associations by category of eosinophil and lymphocyte
counts with cardiovascular diseases were similar between
acute and stable patient states (see online supplementary
ﬁgures S10 and S11). Considering linear associations with
eosinophil count, we found some evidence that higher
stable eosinophil counts were weakly associated with
increased risk of non-fatal MI (HR per 0.1×109/L higher
eosinophil count was 1.02, 95% CI 1.01 to 1.04,
p=0.0088) and PAD (HR 1.03, 95% CI 1.01 to 1.04,
p=0.003; see online supplementary ﬁgure S12). These
associations were weak relative to the distribution of
eosinophil counts in our population (SD 0.16×109/L).
When we split the follow-up time at 6 months, we found
that higher eosinophil counts were associated with
slightly increased risk of non-fatal MI or PAD from
6 months onwards (see online supplementary ﬁgure
S13). There were no signiﬁcant interactions with age or
sex, and a sensitivity analysis excluding patients on loop
diuretics made little difference to the results.
There was considerable variability but minimal trend
over time between repeat measurements of stable
eosinophil counts; the SD of differences between two
consecutive measurements was 0.14×109/L and the cor-
relation coefﬁcient was 0.597 (see online supplementary
ﬁgure S14). For stable lymphocyte counts the SD of dif-
ferences between two consecutive measurements was
0.59×109/L and the correlation coefﬁcient was 0.706
(see online supplementary ﬁgure S15).
DISCUSSION
Summary of main findings
In a general population without pre-existing cardiovascu-
lar disease, we found that low eosinophil and lympho-
cyte counts were associated with increased short-term
incidence of heart failure, unheralded coronary death
and ventricular arrhythmia/sudden cardiac death as the
Figure 3 Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over
the first 6 months ‘Low eosinophils’ are the lowest category (<0.05) compared with the middle category (0.15−0.25). ‘Low
lymphocytes’ are the lowest category (<1.45) compared with the middle category (1.85−2.15). HRs are adjusted for age, sex,
deprivation, ethnicity, smoking, diabetes, systolic blood pressure, body mass index, total cholesterol, HDL cholesterol, eGFR,
atrial fibrillation, autoimmune conditions, inflammatory bowel disease, COPD, cancer, statin use, blood pressure medication and
acute conditions at the time of blood testing. COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration
rate; HDL, high-density lipoprotein.
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initial presentation of cardiovascular disease, and of
non-cardiovascular death. Previous studies have sug-
gested such associations among patients with pre-existing
heart failure,2–5 but our study is the ﬁrst to demonstrate
them in a healthy population. We also demonstrated
lack of association with other cardiovascular diseases
such as angina, non-fatal MI and stroke.
Possible explanations
Eosinophils and lymphocytes are two different classes of
immune cells with very different functions, so it seems
remarkable that they have a similar pattern of associ-
ation with speciﬁc cardiovascular diseases. As this is an
observational study, residual confounding cannot be
excluded, but low eosinophil and low lymphocyte counts
were not associated with major cardiovascular disease
risk factors (table 1, see online supplementary tables S4
and S5) and our associations were robust to a range of
multivariable adjustments. Reverse causation (eg,
patients developing low eosinophil count as a conse-
quence of undiagnosed heart failure) is also an unlikely
explanation for our ﬁndings, because we obtained con-
sistent results in a sensitivity analysis excluding patients
on loop diuretics. One explanation for our ﬁndings is
that low eosinophil and lymphocyte counts may be
markers of frailty, malnutrition15 or immune suppres-
sion,37 which increase the risk of speciﬁc cardiovascular
diseases and non-cardiovascular death. Another poten-
tial explanation is that high levels of endogenous miner-
alocorticoids increase the risk of heart failure via sodium
retention, and also suppress eosinophil and lymphocyte
counts (adrenal insufﬁciency may be associated with
eosinophilia38 and lymphocytosis39). A third explanation
involves interleukin-5 (IL-5), which mediates the release
of eosinophils into the bloodstream40 and is involved in
differentiation of B lymphocytes to immunoglobulin-
secreting cells.41 Variants in the IL-5 gene are associated
with coronary artery disease,42 and in mouse studies
macrophage-speciﬁc overexpression of IL-5 led to
increased secretion of IgM antibodies that inhibit uptake
of oxidised low-density lipoprotein, with consequent
inhibition of atherosclerosis.43 In cross-sectional studies,
blood levels of IL-5 were strongly associated with eosino-
phil counts44 and decreased subclinical atherosclerosis,45
and cohort studies among critical care patients found
that higher IL-5 was associated with better outcomes.46
We are not aware of any longitudinal cohort studies
among the general population which have investigated
the association of IL-5 and cardiovascular events; we
hypothesise that such an association exists.
Association of eosinophil counts with coronary disease
In contrast to heart failure and unheralded coronary
death, we found a weak positive association of increasing
eosinophil count with increasing risk of MI. Previous
studies reported a much stronger association;10 11 this
may be because we adjusted more completely for other
cardiovascular risk factors (higher eosinophil count was
associated with higher BMI, smoking, diabetes and
deprivation; see table 1). Genome wide association
studies found that a non-synonymous single nucleotide
polymorphism rs3184504[T] in SH2B3 is associated with
higher eosinophil count and MI;47 given that our results
did not show a strong association of eosinophil count
with MI, it seems likely that the causal pathway from
rs3184504[T] is not mediated by eosinophils.
Therapeutic implications
Anti-IL5 therapy is being investigated as a therapy for
asthma, which is characterised by an overactive immune
response and high eosinophil counts.48 If IL-5 truly has
an atheroprotective effect, patients with asthma treated
with anti-IL-5 may potentially be at increased cardiovas-
cular risk, and this should be monitored in clinical trials
and postmarketing surveillance. More broadly, this study
suggests that eosinophil and lymphocyte counts should
be interpreted in a more nuanced way in clinical prac-
tice. Currently they inform clinical management only if
the results are outside the ‘normal’ (reference) range.
Clinical reference ranges for eosinophil and lymphocyte
counts are based on the distribution of cell counts
among the population, and are not standardised
between laboratories; in our university hospital, the ref-
erence ranges are 0–0.40×109/L for eosinophils and
1.20–3.65×109/L for lymphocytes. Thus, low eosinophil
counts are considered ‘normal’ even though they are
associated with increased risk of heart failure and death.
Research implications
We recommend that these ﬁndings are replicated in
bespoke cohort studies, with blood counts performed
under standardised conditions and concurrent measure-
ment of IL-5. It would also be of interest to study
lymphocyte subsets, as different types of lymphocytes are
affected by different regulatory mechanisms.
Associations of lymphocyte subsets with cardiovascular
diseases have only been investigated in small studies with
only a few hundred patients.49 Findings from highly phe-
notyped, bespoke cohorts will complement the ‘real-
world’ epidemiological ﬁndings of this study and yield
further mechanistic insights.
Limitations
Although our study has strengths—large size, population
base, extensive adjustment for potential confounders—it
also has important limitations. One of the main limitations
is the selection bias, as participants were only included if
they had a full blood count performed in usual clinical
care, and the indications for this test could vary widely.
However, we investigated conditions and medication that
may acutely affect leucocyte counts, and obtained consist-
ent results in a range of sensitivity analyses, so we consider
that our results are generalisable. Another limitation is
that the measurement of lymphocyte and eosinophil
counts was undertaken by a large number of different
laboratories without study-wide protocols; this may have
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led to underestimating the association because of random
error (regression dilution bias).
As our study was based on electronic health records,
some values of baseline variables were missing for some
patients, but we obtained similar results by imputing
missing data using two different methods. The ascertain-
ment of end points was via routinely coded clinical data,
without end point adjudication;50 however, any failures
in end point recording are likely to be non-differential
in relation to the eosinophil count. Finally, as with any
observational study, the results cannot be taken to imply
causation because there is the possibility of residual con-
founding. We feel this is unlikely because of the strength
of the associations observed and the wide range of
potential confounders included in our models.
CONCLUSIONS
Low eosinophil and lymphocyte counts were strongly
associated with increased short-term incidence of heart
failure and coronary death in a healthy population. This
may have implications for monitoring the cardiovascular
safety of anti-IL-5 therapy for asthma, and for the inter-
pretation of these tests in clinical practice.
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